Emerging studies suggests a powerful alliance between tirzepatide , the dual GIP and GLP-1 receptor agonist, and NAD+ . While this medication and retatrutide have demonstrated remarkable efficacy in treating metabolic dysfunction and facilitating body composition changes, evidence now reveals that bolstering mitochondrial function with NMN could si